Aerpio Therapeutics: Is a biopharmaceutical company focused on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye. The lead programs include a Tie2 activator for diabetic retinopathy (DR) and a hypoxia-inducible factor α (HIF-α) stabilizer for the treatment of inflammatory bowel disease. The lead compound for the Tie2 program, AKB-9778, recently completed a proof-of-concept, Phase 2a study (TIME-2). AKB-4924, the lead compound in our HIF-α stabilization program, has recently completed a Phase 1a study.
Employees: 11-50
Total raised: $98M
Founded date: 2011
Investors 1
| Date | Name | Website |
| - | Montrose C... | montroseca... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 16.03.2017 | - | $40M | - |
| 23.04.2014 | - | $22M | - |
| 06.11.2013 | Series A | $9M | - |
| 30.08.2012 | Series A | $27M | - |
Mentions in press and media 18
| Date | Title | Description |
| 16.03.2017 | Aerpio Pharmaceuticals Raises $40M from OrbiMed | CINCINNATI--(BUSINESS WIRE)--Aerpio Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced the successful completion of its reverse merger transaction with Aerp... |
| 16.03.2017 | Aerpio Pharmaceuticals Raises $40M from Novartis | CINCINNATI--(BUSINESS WIRE)--Aerpio Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced the successful completion of its reverse merger transaction with Aerp... |
| 16.03.2017 | Biopharmaceutical Company Aerpio Pharmaceuticals Raises $40M | Aerpio Pharmaceuticals, Inc., a Cincinnati, OH-based biopharmaceutical company focused on advancing treatments for ocular diseases, completed its reverse merger transaction with Aerpio Therapeutics, Inc. and Aerpio Acquisition Corp., a whol... |
| 29.07.2014 | VC investment shoots up among Midwest healthcare startups | A number of large medical device deals in Minnesota help it clinch the spot as venture darling: The state had four deals that were more than $20 million apiece – Holaira raised $42 million for its lung device that treats COPD; Inspire Medic... |
| 23.04.2014 | Aerpio Therapeutics Closes $22M Financing | Aerpio Therapeutics, Inc., a Cincinnati, OH-based clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, closed a $22m financing. The round was led by new investor OrbiMed, with participati... |
| 23.04.2014 | Aerpio Therapeutics Closes $22M Financing | CINCINNATI, OH, Clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced that it closed a $22M financing round. >> Click here for more funding data on Aerpio Therapeu... |
| 23.04.2014 | OrbiMed leads $22m round for Aerpio Therapeutics | Biopharmaceutical startup Aerpio Therapeutics has secured $22m in a round led by venture capital firm OrbiMed. Novartis |
| 07.11.2013 | Aerpio Therapeutics Closes $9M Series A-2 | CINCINNATI, OH, clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases has closed a new $9 million extension to the $27 million Series A raised in 2012. >> Click here for more fundi... |
| 06.11.2013 | Aerpio Therapeutics Completes $9M in Series A Funding | Aerpio Therapeutics, Inc., a Cincinnati, OH-based clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, completed a new $9m extension to its $27m Series A raised in 2012 (read here). The r... |
| 04.02.2013 | They’re not yet Bostons, but these 5 areas are growing into hubs for life sciences innovation | Westchester/New Haven The corridor between Boston and New Jersey is becoming a hub of its own thanks to new incubator developments and state and local efforts to encourage life sciences research and investment. The report also calls attenti... |
Show more